Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich's Q3 Revenues, R&D Spend Rise 14 Percent as Profit Grows 5 Percent

NEW YORK (GenomeWeb News) — Sigma-Aldrich yesterday said third-quarter revenue rose 14 percent as R&D spending increased 14 percent and profit widened 5 percent.
 
Total receipts for the three months ended Sept. 30 increased to $503.2 million from $441.4 million year over year.
 
R&D spending increased to $15 million from $13.2 million year over year.
 
The company said profit increased to $71.6 million from $68.4 million in the year-ago period. 
 
Sigma-Aldrich said it had around $202.8 million in cash and equivalents as of Sept. 30.
 
The company said it expects organic sales to grow around 7 percent in the fourth quarter and for the full fiscal year.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.